Search

To observe the efficacy and safety of Guihuang Formula (GHF) in treating patients with type III prostatitis and Chinese medicine syndrome of dampness-heat and blood stasis.Sixty-six patients diagnosed with type III prostatitis with dampness-heat and blood stasis syndrome were randomly divided into the treatment group (GHF) and the control group (tamsulosin) using a random number table, with 33 cases each group. The treatment group received GHF twice a day, and the control group received tamsulosin 0.2 mg once daily before bedtime. Patients in both groups received treatment for 6 weeks and was followed up for 2 weeks. The outcomes included the National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI) score, Chinese Medicine Symptoms Score (CMSS), expressed prostatic secretions (EPS) and adverse events (AEs).After treatment, the NIH-CPSI total score and domain scores of pain discomfort, urination and quality of life decreased significantly from the baseline in both groups (P0.05). The CMSS score decreased in both groups (P0.05). The WBC count decreased and lecithin body count increased in both groups (P0.05). GHF showed a more obvious advantage in reducing the pain discomfort and quality of life domain scores of NIH-CPSI, reducing the CMSS score, increasing the improvement rate of the WBC and lecithin body counts, compared with the control group (P0.05). There were no significant differences in decreasing urination domain score of NIH-CPSI between two groups (P0.05). In addition, no serious AEs were observed.GHF is effective in treating type III prostatitis patients with dampness-heat and blood stasis syndrome without serious AEs. (Registration No. ChiCTR1900026966).

Objective This study evaluated the quality of randomized controlled trials (RCTs) on chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Methods We searched PubMed, Web of Science, and Embase for RCTs (original articles) on CP/CPPS published from database establishment to 2021. The RCT quality assessment was performed using the Consolidated Standards of Reporting of Trials (CONSORT) statement and the improved Jadad scale. Results In total, 77 RCTs were included. According to the evaluation, 26 (33.77%) papers presented the description of the specific random methods, only 6 (7.79%) papers described the allocation concealment methods, and 26 (33.77%) articles referred to the “blind method”. Of the RCTs, 34 (44.16%) papers recorded the number of patients who withdrew from the study, and 67 (87.01%) papers reported adverse reactions. However, few reports mentioned the sample size calculation, clinical trial registration, or information about the relevant research programs and funding. In addition, 19 (24.68%) reports had Jadad scale scores of ≥ 4 points, and 58 (75.32%) reports had Jadad scale scores of ≤ 3 points. Conclusion To date, the quality of RCT reports on CP/CPPS needs to be further improved, and the results of the RCTs should be accepted and utilized cautiously. It is suggested that researchers should follow the CONSORT statement and the improved Jadad scale to standardize the design and implementation of RCTs to improve the quality of RCTs and provide reliable evidence for the treatment of CP/CPPS.

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a common urological disease, and research on CP/CPPS has increased over the past 50 years. However, few studies have statistically analyzed these publications. In this work, we conducted the knowledge domain and highlighted current research hotspots and emerging trends in CP/CPPS from 1970 to 2020 based on VOSviewer and CiteSpace.Relevant original articles were obtained from the Web of Science (WoS) database between 1970 and 2020. VOSviewer and CiteSpace software were used to perform the analysis and visualization of scientific productivity and emerging trends.Our results show that the articles related to CP/CPPS have dramatically increased every year from 1 publication in 1970 to 111 publications in 2020. The USA dominated the field in all countries, and Queen's University (Canada) has more extensive cooperating relationships with other institutions. J. Curtis Nickel may have a significant influence on CP/CPPS research with more publications and cocitations. The Journal of Urology is the foremost productive journal and has the most citations of all the journals. A total of 11 major clusters were explored based on the reference cocitation analysis (RCA). Definition, incidence rate or clinical characteristics, etiology or pathogenesis, epidemiological studies (cross-sectional study and cohort study), clinical studies (inflammation, pain, lower urinary tract symptoms (LUTS), α-blockers, antibiotic) and relationships with other diseases [benign prostatic hyperplasia (BPH), prostate cancer, sexual dysfunction] are the knowledge bases for CP/CPPS research. The treatment mode also changed gradually from anti-inflammatory therapy to symptom improvement, and NIH-CPSI was taken as the evaluation criterion.This scientometric study comprehensively reviewed publications related to CP/CPPS during the past 50 years using quantitative and qualitative methods, and the information provides some references for scholars to conduct further research on CP/CPPS.

To explore the possible mechanism of Huanshao Capsules (HSC) protecting the reproductive function in rats with ornidazole-induced asthenozoospermia (AZS).Forty SD male rats were randomly divided into four groups of equal number, blank control, AZS model control, HSC and L-carnitine (LC) intervention. The AZS model was established in the latter three groups of rats by intragastrical administration of ornidazole at 400 mg/kg/d for 28 days, and meanwhile the animals in the HSC and LC groups were treated by gavage of HSC at 0.31 g/kg/d and LC at 100 mg/kg/d, respectively. Then, all the rats were killed for examination of the LC content, sperm concentration, sperm motility and expression of OCTN2 mRNA in the epididymis and observation of the histopathological changes in the testis tissue.Compared with the AZS model controls, the rats in the HSC and LC groups showed significantly increased LC content (2 880.3 vs 6 366.5 and 6 934.7 mg/L, P0.01), sperm concentration (［34.58 ± 10.25］ vs ［46.19 ± 14.23］ and ［42.25 ± 6.11］ ×10⁶/ml, P0.01), sperm motility (［42.59 ± 7.54］% vs ［61.34 ± 7.98］% and ［61.34 ± 7.98］%, P0.01) and expression of OCTN2 mRNA in the epididymis (26.07% vs 27.26% and 27.15%, P0.01). The animals of the HSC group exhibited a higher comparability than those of the LC group to the blank controls in the morphology, arrangement and activity of spermatogenic cells.HSC can protect the reproductive function and improve sperm concentration and motility in the model rats with ornidazole-induced AZS, which may be associated with its abilities of up-regulating the expression of OCTN2 mRNA and increasing the LC content in the epididymis.

To evaluate the safety and efficacy of Chinese medicine, Qiaoshao formula combined with dapoxetine was used for the treatment of premature ejaculation in a real-life setting. Nine hundred and five males diagnosed with premature ejaculation were reviewed in this retrospective cohort study. We divided the patients into two groups: dapoxetine alone and Qiaoshao formula combined with dapoxetine according to actual interventions provided to patients in clinics. The perceived intravaginal ejaculation latency time and the premature ejaculation profile measures markedly improved in both groups. However, in men with severe premature ejaculation (baseline perceived intravaginal ejaculation latency time

To explore the protective effect of the Chinese medicinal prescription Linggui Fang (LGF) on the reproductive system of the ornidazole-induced asthenospermia (AS) rat and its possible action mechanisms.Forty male SD rats weighing 200－230 g were equally randomized into four groups, blank control, AS model control, LGF treatment and L-carnitine (LC) intervention. The AS models were made in the latter three groups by intragastrical administration of ornidazole at 400 mg/kg. Meanwhile, the rats in the LGF group were treated intragastrically with LGF at 17.5 g/kg, those in the LC group with LC at 100 mg/kg, and the control animals with 0.5% sodium carboxymethylcellulose (CMC-Na), all once a day for 4 successive weeks. Then, all the rats were sacrificed for examination of the semen parameters, determination of the LC content and OCTN2 mRNA expression in the epididymis and observation of the histopathological changes in the testis.Compared with the AS model controls, the rats in the other groups showed significantly higher percentages of progressively motile sperm and total motile sperm (P0.01) as well as a higher LC content in the epididymis (P0.01), but no statistically significant difference in sperm concentration (P0.05). The expression of OCTN2 mRNA was remarkably upregulated in the LGF and LC groups in comparison with that in the AS model control (P0.05). Compared with the rats in the blank control group, the AS model controls exhibited markedly increased morphologically abnormal seminiferous tubules, irregularly arranged, with narrowed lumens and reduced numbers of sperm and sperm cells, as well as significantly increased hollow seminiferous tubules with deficient and disorderly arranged spermatogenic cells and partial epithelial degeneration and vacuolization. Those in the LGF and LC groups, however, manifested almost normal testicular histomorphology, with basically regular arrangement of different layers of seminiferous tubules.①Ornidazole induces AS in rats by reducing the LC content in the epididymis, while LGF can improve the sperm motility and testicular morphology of the rats and upregulate the expression of OCTN2 mRNA in the epididymis by increasing the LC concentration.

To evaluate the effect and safety of Qianlieshutong Capsules (QC) in the treatment of BPH.We searched 10 Chinese and English databases up to July 2019 for randomized controlled trials (RCT) on treatment of BPH with QC followed by a meta-analysis on the included articles using Cochrane Handbook 5.1.0 and Revman5.3 software.A total of 18 RCTs involving 1 802 cases of BPH were included out of the 175 articles identified. The baseline data from the RCTs were all comparable. Compared with the controls, the patients treated with QC showed a significantly higher rate of clinical effectiveness and better improvement in IPSS as well as in the maximum urinary flow rate (Qmax), postvoid residual urine (PVR) and prostate volume after 3 months of medication. No serious adverse drug events or reactions were reported.The existing data and methodology indicate the efficacy and safety of Qianlieshutong Capsules in the treatment of BPH, which, however, has to be further verified by more well-designed large-sample multi-center high-quality randomized controlled trials.

To evaluate the clinical effectiveness and safety of the Chinese medicine (CM) Qixiong Zhongzi Decoction (, QZD) in the treatment of patients with idiopathic asthenozoospermia.A total number of 66 patients with idiopathic asthenozoospermia were included and randomly divided into treatment and control groups by SAS-generated code from January 2015 to August 2016, 33 patients in each group. Patients in the treatment group were administered with 150 mL of QZD twice a day, whereas those in the control group were given 1 g of levocarnitine oral liquid twice a day. The two groups received the indicated medication for 12 weeks and were then followed up for 4 weeks. The primary outcome was sperm motility, and the secondary therapeutic indices were sperm volume, density, pregnancy probability, and CM syndrome score. The comparison between groups was carried out at 4, 8 and 12 weeks, respectively. The safety was determined before and after treatment.(1) Drop-off: 5 cases (7.58%) were lost after treatment (2 from the treatment group and 3 from the control group). (2) Primary outcomes: after 8- and 12-week treatment, the progressive sperms in the two groups were significantly higher than the baseline (all P0.05); however, the treatment group showed greater improvement compared with the control group at 12-week treatment (22.7% ± 9.0% vs. 14.1% ±8.8%, P0.05). The increasement of non-progressive grade sperms at both groups was observed at 8- and 12-week treatment with statistical difference (all P0.05), however, the treatment group showed remarkable improvement compared with the control group at 12-week treatment (38.7% ±14.1% vs. 26.2% ±15.4%, P0.05). (3) Secondary outcomes: no significant statistical differences were found in semen volume and density (4, 8, and 12-week treatment) and pregnancy probability of patients' wives (12-week treatment) between two groups (all P0.05), however, the CM syndrome score of the treatment group significantly declined compared with baseline level at each time points (all P0.05). (4) Safety: no obvious side reactions were found during the treatment in both groups.QZD could improve the progressive and non-progressive grade sperm in the treatment of idiopathic asthenozoospermia. It is safe with no obvious side effects.

To observe the effificacy and safety of Qiaoshao Formula (, QSF) on patients with lifelong premature ejaculation (LPE) of Gan (Liver) depression and Shen (Kidney) defificiency syndrome.A total of 60 LPE patients were randomly divided into treatment (QSF) and control (dapoxetine) groups. The treatment group received QSF twice a day and the control group received dapoxetine 1 to 2 h prior to planned sexual intercourse for 4 weeks. The outcomes included intra-vaginal ejaculation latency time (IELT), premature ejaculation diagnostic tool (PEDT), clinical global impression of change (CGIC), scores of Chinese medicine symptoms (CMSS), sex life satisfaction (SLS) and adverse events (AEs).In the treated group, the median IELT was 3 min vs. 1.5 min before and after treatment (P0.05). PEDT in the treated group was reduced to 11.76±1.68 from 15.83±2.30 after treatment (P0.05). Besides, patient's SLS was improved from 1.30±0.05 to 6.30±0.04 (P0.05), and spouse's SLS was increased from 1.30±0.to 6.10±0.06 (P0.05); CMSS was decrease from 14.86±3.02 to 9.62±2.87 (P0.05). In addition, no significant AE was observed in both groups.QSF may be effective and safe on LPE patients with Gan depression and Shen defificiency syndrome.

To observe the intervention effect of Qiaoshao Prescription (QSP) on premature ejaculation (PE) induced by 8-OH-DPAT in male rats and explore its possible action mechanism.Seventy-two male Wistar rats were equally randomized into six groups, blank control, PE model control, low-, medium- and high-dose QSP, and dapoxetine. The PE model was established by injection of 8-OH-DPAT into the subarachnoid space of the lumbosacral spinal cord. Four weeks after modeling, the rats in the blank control and PE model control groups with gavaged with normal saline at 10 ml/kg/d, those in the low-, medium- and high-dose QSP groups with QSP at 5, 10 and 20 g/kg/d respectively once a day, and those in the dapoxetine group with dapoxetine hydrochloride at 300 mg/kg at 3 hours before mating. Forty-five female Wistar rats were injected subcutaneously with 20 μg estradiol benzoate after removal of bilateral ovaries to induce estrous estrus. Two and 4 weeks later, the male rats were mated with the female ones for 30 minutes per time and meanwhile observed for the mating behavior of the males, including mounting latency (ML), intromission latency (IL), ejaculation latency (EL), mounting frequency (MF), intromission frequency (IF), and ejaculation frequency (EF). After the 4th week of mating, the hypothalamus of the animals was isolated and weighed, and the content of 5-hydroxytryptamine (5-HT) was measured.Compared with the blank control group, the PE model controls showed significantly decreased content of 5-HT in the hypothalamus(1 257.1 vs 923.4 ng/g, P0.05), ML (［11.22 ± 3.60］ vs ［8.69 ± 2.48］ s, P0.05), IL (［22.33 ± 2.45］ vs ［12.08±1.39］ s, P0.05), MF (［13.28 ± 3.24］ vs ［7.53 ± 1.84］ times, P0.05), and EL (［712.35 ± 36.77］ vs ［502.35 ± 46.72］ s, P0.05). In comparison with the PE model controls, the rats of the QSP and dapoxetine groups exhibited remarkably increased content of 5-HT (P0.05) and prolonged EL (P0.05).Qiaoshao Prescription can prolong EL in PE rats, which might be associated with the increased content of 5-HT in the hypothalamus. Further studies, however, are needed on its underlying mechanisms.目的: 观察翘芍方对运用5-羟色胺1A（5-HT1A）受体激动剂8-羟基-2-(二丙基氨基)四氢萘氢溴酸盐（8-OH-DPAT）建立的早泄动物模型的干预效果，并探讨其可能的作用机制。方法: 将雄性Wistar大鼠72只随机分为空白组、模型组、翘芍方组（高、中、低剂量）和达泊西汀组，各12只，以8-OH-DPAT腰骶脊髓节段蛛网膜下腔囊内注射建立早泄动物模型。造模成功后连续给药干预4周，模型组、空白组每天用生理盐水［10 ml/(kg·d)］灌胃；翘芍方低［5g/(kg·d)］、中［10g/(kg·d)］、高［20g/(kg·d)］剂量组，每天灌胃1次；达泊西汀组合笼前3 h给予300 mg/kg盐酸达泊西汀灌胃。雌性Wistar大鼠45只，摘除双侧卵巢后，于合笼前36 h皮下注射苯甲酸雌二醇20μg/只以诱导雌鼠发情。在第2周和第4周时，分别将雄性大鼠和激素诱导的雌性大鼠合笼，进行交配实验，每次30 min。检测指标：观察和记录雄鼠的交配行为，包括骑跨潜伏期(ML)、插入潜伏期(IL)、射精潜伏期(EL)、骑跨次数(MF)、插入次数(IF)、射精次数(EF)。第4周交配试验后，分离出下丘脑并称重，测定5-羟色胺（5-HT）含量。结果： 与空白组相比，模型组5-HT含量923.4 ng/g，ML（8.69±2.48）s、IL（12.08±1.39）s、MF（7.53±1.84）次、EL（502.35±46.72）s分别低于空白组的5-HT含量1 257.1 ng/g，ML（11.22±3.60）s，IL（22.33±2.45）s、MF（13.28±.24）次、EL（712.35±36.77）s，差异均有统计学意义（P＜0.05）；药物干预后，与模型组比较，翘芍方高剂量组和达泊西汀组的5-HT含量均升高，差异有统计学意义（P＜0.05）；与模型组比较，翘芍方各剂量组和达泊西汀组EL明显延长，差异有统计学意义（P＜0.05）。结论： 翘芍方可延长早泄大鼠的射精潜伏期，这可能与其增加了下丘脑5-HT含量有关，具体机制还需进一步研究。

To explore the feasibility and practicability of establishing a rat model of premature ejaculation (PE) by injection of 8-OH-DPAT into the subarachnoid space of the lumbosacral spinal cord segments.Twenty-four male Wistar rats were equally randomized into a PE model and a blank control group. The PE model was established by injection of 8-OH-DPAT in 10 ml normal saline at 0.8 mg per kg of the body weight per day into the subarachnoid space of the lumbosacral spinal cord segments and the control rats were injected with the same volume of normal saline only, both for 4 weeks. Another 24 female Wistar rats were injected subcutaneously with benzoic acid estradiol at 20 μg to induce estrus at 36 hours before mated with the male animals. At 2 and 4 weeks, the male rats were mated with the female ones for 30 minutes each time and meanwhile observed for their mating behavior indicators, such as mount latency, intromission latency, ejaculation latency, mount frequency, intromission frequency, and ejaculation frequency.Compared with the controls, the PE model rats showed a significantly lower ejaculation latency (［712.35 ± 36.77］ vs ［502.35 ± 46.72］ s, P0.05), mount latency (［11.22 ± 3.60］ vs ［8.69 ± 2.48］ s, P0.05), mount frequency (13.28 ± 0.24 vs 7.53 ± 1.84, P0.05), and intromission latency (［22.33 ± 2.45］ vs ［12.08 ± 1.39］ s, P0.05), but a remarkably higher ejaculation frequency (2.01 ± 0.48 vs 4.26 ± 0.89, P0.05). No statistically significant difference was observed between the control and model animals in the intromission frequency (7.49 ± 2.21 vs 6.45 ± 1.89, P0.05).A rat model of premature ejaculation was successfully established by injection of 8-OH-DPAT into the subarachnoid space of the lumbosacral spinal cord segments, which is of great significance for further study of the mechanism of premature ejaculation.目的: 探讨运用8-羟基-2-(二丙基氨基)四氢萘氢溴酸盐（8-OH-DPAT）腰骶脊髓节段蛛网膜下腔囊内注射建立早泄大鼠模型的可行性及实用性。方法: 选择雄性Wistar大鼠24只，按照1∶1随机分为2组，A组:空白对照组（等量生理盐水）；B组:模型组［将8-OH-DPAT 溶于10 ml生理盐水中，按0.8 mg/(kg·d)，进行腰骶脊髓节段蛛网膜下腔囊内注射，持续4周］。雌性Wistar大鼠24只，摘除卵巢后，于合笼前36 h皮下注射苯甲酸雌二醇20 μg以诱导雌性大鼠发情。在第2周和第 4周时，将雄性大鼠和激素诱导的雌性大鼠合笼，进行交配实验，每次30 min。观察和记录雄性大鼠的交配行为，包括骑跨潜伏期、插入潜伏期、射精潜伏期、骑跨次数、插入次数、射精次数。结果： 药物干预后，B组的射精潜伏期［（502.35±46.72） s］明显低于A组［（712.35±36.77） s］，骑跨潜伏期［（8.69±2.48） s］明显低于A组［（11.22±3.60） s］，骑跨次数［（7.53±1.84）次］明显低于A组［（13.28±0.24）次］，插入潜伏期［（12.08±1.39） s］明显低于A组［（22.33±2.45） s］，射精次数［（4.26±0.89）次］明显高于A组［（2.01±0.48）次］，差异均有统计学意义(P均0.05）；插入次数［（6.45±1.89）次］与A组［（7.49±2.21）次］无明显差异(P0.05)。结论： 用8-OH-DPAT腰骶脊髓节段蛛网膜下腔囊内注射，可以较好的建立早泄大鼠模型，该模型对深入研究早泄机制有十分重要的意义。.

To make a real-world study on the efficacy and safety of traditional Chinese medicine (TCM) combined with sildenafil in the treatment of erectile dysfunction (ED) that failed to respond to TCM medication.This study included 1 038 ED patients with the International Index of Erectile Function-5 (IIEF-5) scores ≤21 and improvement30% after 4 weeks of TCM medication, differentially diagnosed with kidney-yang or kidney-yin deficiency syndrome. We administered TCM combined with sildenafil (Viagra, Pfizer Pharmaceutical Co., Ltd) at 100 mg 1 hour before sexual intercourse. After 2 and 4 weeks of medication, we recorded the scores in IIEF-5, erection hardness, Sexual Encounter Profile question 2 (SEP-2: whether vaginal penetration is successful), SEP-3 (whether sexual intercourse is successful), and TCM Syndromes Scale as well as the indexes of routine blood, urine, liver function, and renal function of the patients, and compared them with those obtained before treatment.No serious adverse reactions were observed in any of the patients. Compared with the baseline, the patients achieved significantly increased IIEF-5 scores after 2 and 4 weeks of medication (15.01 ± 2.25 vs 16.96 ± 2.55 and 19.41 ± 2.82, P0.05), penileelectionhardness remarkably improved at 4 weeks (3.36% vs 44.58%, P0.05), and the positive answers to SEP-2 and SEP-3 both markedly increased at 2 (38.11% vs 90.49%, P0.05; 22.01% vs 63.77% , P0.05) and 4 weeks (38.11% vs 96.95% , P0.05; 22.01% vs 89.73%, P0.05).TCM combined with sildenafil is safe and effective in the treatment of ED in Chinese men, which can significantly improve the IIEF-5 score and erection hardness of the patients.目的: 观察真实世界中药联合西地那非治疗中药无效型勃起功能障碍（ED）疗效及安全性。方法: 选取1038例中药治疗无效（服用4周中药，治疗后IIEF-5评分改善率30%且≤21分）的ED患者，重新辨证为肾阳虚证、肾阴虚证，中药同时联合西地那非100 mg性生活前1 h服用，在2、4周后观察患者IIEF-5、勃起硬度分级（EHS）、性生活日志问题2（SEP2）、性生活日志问题3（SEP3）、中医证候评分及血常规、尿常规、肝功能( ALT) 、肾功能( BUN、Cr)等指标，并与治疗前对比。结果: 所有患者未发现严重的不良反应。治疗2、4周后IIEF-5评分［(16.96±2.55)分、(19.41±2.82)分］均有不同程度提高，差异有统计学意义(P0.05)；治疗4周后EHS4比例（44.58%）上升，与治疗前EHS4（3.36%）相比有统计学差异（P0.05）；治疗2、4周后，SEP2肯定回答的比例分别为90.49%,96.95%，与治疗前（38.11%）比较，均有统计学差异（P‚0.05）。治疗2、4周后，SEP3肯定回答的比例分别为63.77%、89.73%，与治疗前（22.01%）比较，均有统计学差异（P‚0.05）。结论: 真实世界研究发现中药联合西地那非治疗ED是安全、有效的，能有效提高ED患者IIEF5评分，提高勃起硬度。.

To assess the efficacy and safety of three different Chinese medical principles in treating patients with male infertility (oligospermia/asthenozoospermia).Totally 128 patients with male infertility were classified into 3 groups, i.e., Shen-essence deficiency syndrome, Pi-Shen deficiency syndrome, Shen-deficiency blood-stasis syndrome. They were assigned to the Chinese medical treatment group (96 cases) and the Western medical treatment group (32 cases) by stratified randomization in the ratio of 3: 1. Those in the Chinese medical treatment group were treated with Chinese drugs for Shen invigorating and blood activating, Shen invigorating and Pi supplementing, Shen-qi benefiting. Those in the Western medical treatment group were treated with Clomifene (at the daily dose of 25 mg per day, once daily). Three months consisted of one therapeutic course. The parameters of semen, the pregnancy rate, and adverse reactions were observed.Totally 24 patients dropped out in the two group, 17 in the Chinese medical treatment group (9 patients of Shen deficiency blood stasis syndrome, 5 of Shen-Pi deficiency syndrome, and 3 of Shen-essence deficiency syndrome) and 7 in the Western medical treatment group. Compared with before treatment, there was no statistical difference in the improvement of semen amount at 3 months after treatment between the two groups (P0.05). There was statistical difference in the improvement of semen density, class A semen, class A +B semen, and 1-h activity ratio (P0.05). The improvement was most obvious in Shen deficiency blood stasis syndrome, followed by Shen-Pi deficiency syndrome and Shen-essence deficiency syndrome. The improvement was the weakest in the Western medical treatment group. There was no statistical difference in the improvement of semen amount, semen density, class A semen, or 1-h activity ratio at 3 months after treatment between the two groups (P0.05). Best effect was obtained in improving class A + B semen quality in patients of Shen deficiency blood stasis syndrome, showing statistical difference when compared with the other two syndrome types and the Western medical treatment group (P0.05, P0.01). No obvious adverse reaction occurred in the two groups during the treatment course.Shen invigorating and blood activating method could improve the semen density and semen activities, and it was superior to other therapeutic methods.